PressOctober 27, 2022 Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event
PressOctober 27, 2022 Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon
BlogOctober 26, 2022 Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
BlogOctober 25, 2022 What are Some of the Most Common Misconceptions About Psychedelics?: Mindshifting Moments #15
PressOctober 25, 2022 Silo Pharma – Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
PressOctober 25, 2022 IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
PressOctober 25, 2022 atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
PressOctober 24, 2022 Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs
PressOctober 24, 2022 Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
PressOctober 24, 2022 Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
